Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

32 ta ish

Ish: Effectiveness and Safety of a Shorter Treatment Regimen in a Setting with a High Burden of Multidrug-Resistant Tuberculosis

  1. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011

    Dilrabo Ulmasova, G Uzakova, M N Tillyashayhov +17

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyEurosurveillance201315 iqtibos
    ABI

  2. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

    Armand Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim +4

    MaqolaOchiq kirish201012 iqtibos
    ABI

  3. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

    Andrew Nunn, Patrick Phillips, Sarah Meredith +16

    MaqolaOchiq kirish20196 iqtibos
    ABI

  4. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients

    K. J. M. Aung, Armand Van Deun, Erik De Clercq +4

    Maqola20146 iqtibos
    ABI

  5. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries

    Arnaud Trébucq, V Schwoebel, Zacharie Kashongwe +15

    Maqola20176 iqtibos
    ABI

  6. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study

    Elisabeth Sánchez-Padilla, Caroline Marquer, Stobdan Kalon +5

    Maqola20145 iqtibos
    ABI

  7. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses

    Faiz Ahmad Khan, M Salim, Philipp du Cros +9

    Sharh maqolaOchiq kirishTuberculosis Research and EpidemiologyEuropean Respiratory Journal20174 iqtibos
    ABI

  8. “When Treatment Is More Challenging than the Disease”: A Qualitative Study of MDR-TB Patient Retention

    Kalpita Shringarpure, Petros Isaakidis, Karuna D. Sagili +3

    Maqola20163 iqtibos
    ABI

  9. What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?

    Surendra K. Sharma, Keertan Dheda

    Tahririyat maqolasi20193 iqtibos
    ABI

  10. Drug-resistant tuberculosis in eastern Europe and central Asia: a time-series analysis of routine surveillance data

    Andrei Dadu, Arax Hovhannesyan, Sevim Ahmedov +2

    Maqola20192 iqtibos
    ABI

  11. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  12. Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings

    Giovanni Sotgiu, Simon Tiberi, Rosella Centis +4

    Maqola20162 iqtibos
    ABI

  13. RAWGraphs

    Michele Mauri, Tommaso Elli, Giorgio Caviglia +2

    Maqola20172 iqtibos
    ABI

  14. Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

    S.K. Abidi, Jay Achar, M.M. Assao Neino +34

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyEuropean Respiratory Journal20191 iqtibos
    ABI

  15. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  16. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  17. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  18. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  19. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  25. Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

    Philipp du Cros, Atadjan Khamraev, Zinaida Tigay +15

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyERJ Open Research20201 iqtibos
    ABI